CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法已显示治疗某些血液系统恶性肿瘤的疗效,但CAR-T 细胞给药也伴随不良事件。其中,细胞因子释放综合征(CRS)受到广泛关注。本描述性研究设定检索标准,从Web of Science核心合集(WoSCC)中检索并获取关于CAR-T 细胞相关CRS的文章。使用Microsoft Excel 2019、GraphPad Prism 8、CiteSpace和VOSviewer对这些文献进行文献计量及知识图谱分析。49个国家的295家机构中共有6,623名作者合作发表了1,001篇论文。美国是该领域领先国家,宾夕法尼亚大学是产出最多的机构。
Carl H. June被引次数最多,Daniel W. Lee共被引次数最多。研究热点主要集中于CRS的发病机制、血清生物标志物、管理和治疗药物,以及神经毒性。该领域新兴主题包括:(a)有效治疗和干预CRS的药物;(b)开展相关临床试验以获取真实世界数据;(c)管理CAR-T 细胞疗法相关毒性(CRS和神经毒性);(d)研究治疗多发性骨髓瘤(MM)的BCMA-CAR-T 细胞;(e)优化CAR框架结构以提高CAR-T 细胞的疗效和安全性。文献计量和科学知识图谱分析为探索CAR-T 细胞相关CRS领域提供了独特、客观的视角,并可为研究人员提供新的线索及有价值的参考。
CAR-T cell therapy has demonstrated efficacy in treating certain hematological malignancies.
However, the administration of CAR-T cells is accompanied by the occurrence of adverse events. Among these, cytokine release syndrome (CRS) has garnered significant attention. In this descriptive study, we set the search criteria to retrieve and obtain articles regarding CAR-T cell-related CRS from the Web of Science Core Collection (WoSCC). The bibliometric and knowledge-map analysis of these documents was conducted using Microsoft Excel 2019, GraphPad Prism 8, CtieSpace, and VOSviewer. 6,623 authors from 295 institutions in 49 countries coauthored a total of 1,001 publications. The leading country in this field was the United States. The most productive institution was the University of Pennsylvania. Carl H. June had the most citations, while Daniel W. Lee had the most co-citations.
Research hotspots primarily concentrated on the pathogenesis, serum biomarkers, management, and therapeutic drugs of CRS, alongside neurotoxicity. Emerging topics within this discipline encompassed the following: a. Drugs for effective treatment and intervention of CRS; b. Conducting pertinent clinical trials to acquire real-world data; c. Management of toxicity (CRS and neurotoxicity) associated with CAR-T cell therapy; d.
The study of BCMA-CAR-T cells in multiple myeloma (MM); e. Optimizing the CAR framework structure to enhance the effectiveness and safety of CAR-T cells. A bibliometric and scientific knowledge-map analysis provided a unique and objective perspective for exploring the field of CAR-T cell-related CRS, and may provide some new clues and valuable references for researchers.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。